Vaxcyte Exec Cowan Elvia Executes 3,000‑Share 10b5‑1 Plan, Buying at $25.92 and Selling at $60.00—A Signal of Steady Insider Confidence and Liquidity Management
Insider activity: Cowan Elvia’s disciplined 10b5‑1 buy/sell of Vaxcyte shares shows long‑term confidence in the vaccine pipeline and liquidity strategy.
3 minutes to read
